GSK Gives Up Right To Buy Eniluracil Back From Adherex
This article was originally published in The Pink Sheet Daily
Executive Summary
Adherex has an “accelerated development plan” for the novel chemoenhancer GSK shelved in 2004.
You may also be interested in...
Sanofi-Aventis Gastric Cancer Drug Shows Significant Reduction In Risk Of Death
Company plans to file the oral fluorouracil candidate S-1 in 2009 or 2010.
Sanofi-Aventis Gastric Cancer Drug Shows Significant Reduction In Risk Of Death
Company plans to file the oral fluorouracil candidate S-1 in 2009 or 2010.
Adherex Licenses GSK’s Eniluracil, Estimates Oncologic’s Potential At $1 Bil.
Eniluracil has potential to make the chemotherapy staple 5-fluorouracil more effective, safer and orally active, Adherex maintains. Agent slated to enter new Phase III studies in 2007. Licensing pact valued at up to $220 mil. also gives GSK option on Adherex’ angiolytic agent Exherin.